How to prevent thrombotic diseases? Sergio Fusco, MD

Transcription

1 How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy

2 CONFLICT OF INTEREST DISCLOSURE I have no potential conflict of interest to report

3 OUTLINE OUTLINE EPIDEMIOLOGY AGEING AND THROMBOTIC RISK SIMPLE RISK STRATIFICATION ANTITHROMBOTIC THERAPY VENOUS AND ARTERIAL THROMBOSIS: IS THERE A LINK?

4 Is it worth offering thrombotic prevention to the elderly?

5 Epidemiology of thrombotic diseases European Heart Journal (2016) 37,

6 Risk factors for thrombotic diseases Atherothrombosis VTE-PE Thrombotic events Heart failure. Antithrombotic Therapy and Prevention of Thrombosis. Chest Diagnosis and Treatment of Peripheral Arterial Diseases 2017 ESC Guidelines

7 Eur Heart J Dec 7;36(46):

8 Aging Clin Exp Res (2017) 29:

9 ARE GERIATRIC SYNDROMES ASSOCIATED WITH RELUCTANCE TO INITIATE ORAL ANTICOAGULATION THERAPY IN ELDERLY ADULTS?

10 Patients centred care for Older Adults Prog Cardiovasc Dis ; 57(2):

11 Rapid Screening and Risk assessment tool PADUA SCORE D-DIMER? ANKLE-BRACHIAL INDEX CHA₂DS₂-VASc - HAS-BLED CLINICAL FRAILTY SCALE Antithrombotic Therapy and Prevention of Thrombosis. Chest Diagnosis and Treatment of Peripheral Arterial Diseases 2017 ESC Guidelines

12 PADUA SCORE FOR RISK STRATIFICATION IN VTE VKA/NOAC Antithrombotic Therapy and Prevention of Thrombosis. Chest

13 D-Dimer in VTE Conventional D-dimer cutoff value for VTE (500 mcg/l) Use an age-adjusted D-dimer cutoff (patient s age in years 10 mcg/l) for patients over age 50 years when evaluating for venous thromboembolism (VTE) BMJ. 2013;346:f2492.

14 Ankle-Brachial Index mean age 80 4 year follow up Arch Intern Med. 2013; 163:

15 CHA₂DS₂-VASc 2 High risk HAS-BLED 3 High risk Circulation 2013;125:

16 Proposed algorithm for the management of elderly patients requiring anticoagulation Journal of Pharmacy Practice and Research (2015)

17 Smoking cessation Quitting at older age still Mortality rates CV events New or recurrent stroke Quality of life VTE? Physical Activity Mozaffarian, Circulation 131:e29, 2015 Fleg, Circulation 128:2422, 2013 Enga KF, J Thromb Haemost 2012 Mortality rates CV events New or recurrent stroke Quality of life VTE Moderate-intensity aerobic (endurance) physical activity minimum of 30 min on five days each week vigorous-intensity aerobic activity for a minimum of 20 min on three days each week. I (A) Nelson, Circulation 116:1094, 2007

18 Winston Churchill died at 91 years Asked the secret of his long life : "Cuban cigars, Armenian brandy and no sport!"

19 Systematic review of clinical practice guidelines recommendations about primary cardiovascular disease prevention for older adults BMC Family Practice (2016) 16:104 Therapy for Peripheral Artery Disease

20 Mean age 66 ± 6 European Heart Journal (2016) 36,

21 ANTIPLATELET IN VTE/PE In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, we suggest aspirin over no aspirin to prevent recurrent VTE (Grade 2B). Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016

22 In patients with solid tumors who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylactic dose LMWH or LDUH over no prophylaxis (Grade 2B) European Heart Journal (2016) 36, Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016

23 OACs in elderly

24 Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

25 contraindications for mechanical prophylaxis Suspected or proven peripheral arterial disease Peripheral neuropathy or other causes of sensory impairment Fragile skin, dermatitis, gangrene, or recent skin graft Cardiac failure or severe edema Allergy to material or inability to fit stocking Extreme deformity to the leg, or unusual leg shape or size preventing correct fit Antithrombotic Therapy and Prevention of Thrombosis. Chest Phlebology 2011;26:

26 Venous and Arterial Thrombosis: Is There a Link? Mean age 62 ± 13 Adv Exp Med Biol. 2017;906:273-28

27 N Engl J Med Aug 27. Mean age 70 ± 8 Rivaroxaban plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events.

28 Statins and primary prevention of venous thromboembolism: a systematic review and metaanalysis

29 No OACs users OACs users Mean age 65 ± 10 Patient Preference and Adherence 2015:

30 Take home message Patient-centred approach: INDIVIDUALIZE!

31 Thank you for your attention The good physician treats the disease, the great physician treats the patient who has the disease Sir William Osler

32

33

34 CHA₂DS₂-VASc 2 High risk Mean age 76 ± 4 HAS-BLED 3 High risk J Am Coll Cardiol Dec 10;62(23): CHEST 2013; 143(1):

35 Thromboprophylaxis medical patients with cancer In patients with cancer who have no additional risk factors for VTE, we suggest against routine prophylaxis with LMWH or LDUH (Grade 2B) and recommend against the prophylactic use of VKAs (Grade 1B) In patients with solid tumors who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylactic dose LMWH or LDUH over no prophylaxis (Grade 2B) Antithrombotic Therapy for VTE Disease: CHEST Guideline. Chest 2016

36 BLEEDING VS THROMBOTIC RISK

37 Risk factors for thrombotic diseases Clotting disorders (Thrombophilia) Personal or family history of DVT Obesity/metabolic syndrome Cigarette smoking Heart failure. Atrial Fibrillation Cancer. Being restricted to bed rest. Surgery European Heart Journal (2015) 36,

38

39 contraindications for mechanical prophylaxis Suspected or proven peripheral arterial disease Peripheral neuropathy or other causes of sensory impairment Fragile skin, dermatitis, gangrene, or recent skin graft Cardiac failure or severe edema Allergy to material or inability to fit stocking Extreme deformity to the leg, or unusual leg shape or size preventing correct fit Antithrombotic Therapy and Prevention of Thrombosis. Chest Phlebology 2011;26:

40 Advantages of LMWH over UFH Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016